Low dose naltrexone benefits: what the research shows

The following blog post is for entertainment and informational purposes only. It is not intended to provide medical advice or diagnosis. Please consult your doctor before making any health-related decisions.

Low dose naltrexone benefits a growing range of patients dealing with chronic inflammation, autoimmune conditions, and persistent pain. Naltrexone has been in clinical use since 1984. At a much smaller amount, it operates through a completely different pathway, prompting the body to recalibrate its own immune and pain signaling rather than occupying opioid receptors around the clock. LDN therapy has built a consistent research record over two decades, particularly in conditions where conventional treatments fall short.

Condition	Supporting evidence
Crohn's disease	Smith et al., 2007, American Journal of Gastroenterology
Fibromyalgia	Younger et al., 2013; Aitcheson et al., 2023
Multiple sclerosis	Cree et al., 2010, Annals of Neurology
Chronic pain syndromes	Kim et al., 2020, Current Pain and Headache Reports
Inflammatory skin conditions	Ekelem et al., 2019; Zhou et al., 2026
Chronic fatigue syndrome	Bolton et al., 2020, BMJ Case Reports

How is low dose naltrexone different from standard naltrexone?

At standard doses, naltrexone continuously occupies opioid receptors to curb cravings and block the rewarding effects of addictive substances throughout most of the day. LDN works differently. A licensed provider determines the appropriate amount after reviewing labs and medical history; once metabolized, the drug clears the body in approximately six hours, leaving no residual blockade. That brevity is what makes the therapy work.

The mechanism is counterintuitive. A short blockade of opioid and TLR-4 receptors signals the body that natural endorphin levels have dropped below normal, triggering an adaptive response in neurons, microglia, and white blood cells. The body upregulates endorphin output and recalibrates immune signaling, producing effects that persist well beyond the six-hour window. They deepen with continued use.

What are the low dose naltrexone benefits?

Low dose naltrexone benefits cluster around three areas: inflammation control, pain reduction, and immune modulation. A 2018 review by Toljan and Vrooman in Medical Sciences confirmed all three as core mechanisms of LDN's therapeutic action.

LDN for inflammation. The drug suppresses pro-inflammatory cytokines and reduces overactivation of microglial cells, the brain's primary immune responders. Their chronic overactivation links directly to persistent pain and cognitive symptoms.

Naltrexone for chronic pain. A 2020 systematic review by Kim et al. in Current Pain and Headache Reports found consistent evidence that LDN may reduce pain where neuroinflammation is a driving factor. The effect spans multiple conditions. A double-blind crossover trial by Younger et al. (2013) recorded significant daily pain reductions in fibromyalgia patients, confirmed by a 2023 systematic review from Aitcheson et al. that also noted strong tolerability.

Naltrexone immune system modulation. LDN promotes regulatory T-cell function. This dampens the overactive immune responses central to autoimmune disease, making naltrexone autoimmune research an active field covering conditions from Crohn's disease to lupus. A 2007 study by Smith et al. in the American Journal of Gastroenterology found meaningful clinical improvement in patients with active Crohn's disease.

Dermatological conditions. A 2019 systematic review by Ekelem et al. in JAMA Dermatology identified LDN as a viable option for chronic inflammatory skin diseases. A 2026 clinical review by Zhou et al. in the Journal of the American Academy of Dermatology confirmed its growing role in dermatologic practice.

Multiple sclerosis and fatigue. A pilot trial by Cree et al. (2010) in the Annals of Neurology found that LDN improved quality-of-life scores in MS patients versus placebo. Bolton et al. (2020) documented symptom improvement in chronic fatigue syndrome in a case series published in BMJ Case Reports.

Who should take low dose naltrexone?

Adults with ongoing autoimmune activity, neuroinflammation, or chronic pain that has not responded adequately to standard care are the most common candidates for LDN therapy. The treatment is not appropriate for anyone currently using opioid medications, since receptor blockade would precipitate withdrawal. Pregnancy is also a contraindication.

A licensed provider at Valhalla Vitality reviews each case before any prescription is issued. Availability varies by state.

How long does low dose naltrexone take to work?

Most patients do not notice immediate effects. The homeostatic reset builds gradually. Some people report shifts in sleep quality, pain levels, or fatigue within the first four to six weeks; the beneficial effects become more stable over months. This reflects the underlying biology: the body's adaptive response strengthens incrementally rather than switching on at once.

Naltrexone side effects: what to expect

Naltrexone side effects at low doses are uncommon and generally mild. The most frequently reported are vivid dreams or light sleep disturbance at the start of treatment, since LDN is typically taken at night during the period of initial receptor activity. Mild nausea or headache may also occur. Both tend to resolve within the first few weeks. Serious adverse effects are rare across published clinical studies.

Ready to explore LDN therapy?

A licensed provider reviews your intake and determines whether low dose naltrexone is appropriate for your situation. Book Your Consultation to get started.

FAQ

What are the benefits of low dose naltrexone?

Low dose naltrexone benefits include reduced chronic inflammation, pain relief in conditions such as fibromyalgia, and immune modulation in autoimmune diseases. Research also supports its use in multiple sclerosis and chronic fatigue syndrome. A licensed provider reviews your health history before prescribing.

What conditions does LDN treat?

LDN therapy is used off-label for autoimmune conditions including Crohn's disease and multiple sclerosis, chronic pain syndromes, fibromyalgia, and inflammatory skin conditions. The full range of applicable conditions is assessed during a provider review. Availability varies by state.

How long does low dose naltrexone take to work?

Most patients notice gradual changes over several weeks to months rather than immediately. Sleep quality, pain, and fatigue are typically the first areas to shift. The homeostatic response deepens with continued treatment.

How is low dose naltrexone different from standard naltrexone?

Standard naltrexone produces continuous opioid receptor blockade for addiction treatment. LDN uses a much smaller amount that clears within hours, generating a brief paradoxical signal that triggers a lasting immune and pain-regulatory response. The two approaches work through entirely distinct mechanisms.

Who should take low dose naltrexone?

Adults with autoimmune conditions, chronic neuroinflammation, or refractory chronic pain may be candidates for LDN therapy. It is not appropriate for anyone taking opioid medications, since receptor blockade would cause withdrawal. A licensed provider reviews labs and medical history before prescribing.

Sources

1. Toljan K, Vrooman B. (2018). Low-Dose Naltrexone (LDN): Review of Therapeutic Utilization. Medical Sciences. PubMed
2. Smith JP et al. (2007). Low-Dose Naltrexone Therapy Improves Active Crohn's Disease. American Journal of Gastroenterology. PubMed
3. Younger J et al. (2013). Low-dose naltrexone for the treatment of fibromyalgia. Arthritis & Rheumatism. PubMed
4. Cree BAC et al. (2010). Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology. PubMed
5. Bolton MJ et al. (2020). Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Reports. PubMed
6. Kim PS et al. (2020). Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review. Current Pain and Headache Reports. PubMed
7. Aitcheson N et al. (2023). Low-dose naltrexone in the treatment of fibromyalgia. Australian Journal of General Practice. PubMed
8. Ekelem C et al. (2019). Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions. JAMA Dermatology. PubMed
9. Zhou MH et al. (2026). Low-dose naltrexone for treatment of dermatologic conditions: A clinical review. Journal of the American Academy of Dermatology. PubMed